Search Results
Apr 02, 2026, 06:05 ET Evolveum Tackles IGA Application Onboarding at Gartner IAM Summit and Hosts The 2nd Annual MidPoint Community Meetup
Product Officer Pavol Mederly presented 'The Hidden cost of slow application onboarding in IGA,' addressing a key challenge organizations face — the time and complexity of connecting business applications to IGA platforms. Mederly introduced midPilot, Evolveum's AI-powered onboarding assistant built into
More news about: Evolveum
Apr 02, 2026, 05:26 ET Evolveum aborda la incorporación de aplicaciones IGA en la Cumbre IAM de Gartner
Mederly, presentó 'El coste oculto de la lenta incorporación de aplicaciones en IGA', abordando un desafío clave para las organizaciones: el tiempo y la complejidad de conectar las aplicaciones empresariales a las plataformas IGA. Mederly presentó midPilot, el asistente de incorporación con IA de Evolveum
More news about: Evolveum
Apr 02, 2026, 05:26 ET Evolveum präsentiert auf dem Gartner IAM Summit Lösungen für die Einbindung von IGA-Anwendungen und veranstaltet das 2. jährliche MidPoint Community Meetup
versteckten Kosten einer langsamen Anwendungsintegration in IGA" vor und ging dabei auf eine zentrale Herausforderung ein, mit der Unternehmen konfrontiert sind – den Zeitaufwand und die Komplexität bei der Anbindung von Geschäftsanwendungen an IGA-Plattformen. Mederly stellte midPilot vor, den in midPoint integrierten,
More news about: Evolveum
Apr 02, 2026, 05:25 ET Evolveum aborde la question de l'intégration des applications IGA lors du Gartner IAM Summit et organise la 2ᵉ rencontre annuelle de la communauté MidPoint
application onboarding in IGA » (Le coût caché de la lenteur de l'intégration des applications dans le domaine de l'IGA), abordant un défi majeur auquel les organisations sont confrontées : le temps et la complexité de la connexion des applications d'entreprise aux plateformes IGA. Mederly a présenté midPilot,
More news about: Evolveum
Apr 01, 2026, 13:23 ET Global Traveler Announces 14th Annual Leisure Lifestyle Awards
ResortsThe Excellence CollectionBest Tour OperatorAbercrombie & KentBest Airport for LayoversiGA İstanbul AirportBest Stopover ProgramTAP Air PortugalEighth Consecutive YearBest Leisure AirlineAir
More news about: Global Traveler
Apr 01, 2026, 07:44 ET Evolveum Tackles IGA Application Onboarding at Gartner IAM Summit and Hosts The 2nd Annual MidPoint Community Meetup
Product Officer Pavol Mederly presented 'The Hidden cost of slow application onboarding in IGA,' addressing a key challenge organizations face — the time and complexity of connecting business applications to IGA platforms. Mederly introduced midPilot, Evolveum's AI-powered onboarding assistant built into
More news about: Evolveum
Mar 31, 2026, 08:13 ET 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
critical clinical gap in the domestic market.SSS68 (Long-acting anti-April/BAFF BsAb): Its Investigational New Drug (IND) application for IgA nephropathy has been approved in the US. As the only domestic long-acting bispecific antibody in clinical development targeting the APRIL/BAFF
More news about: 3SBio Inc.
Mar 30, 2026, 08:00 ET Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-IgA1), causing IgA nephropathy.About Primary Immunoglobulin A NephropathyPrimary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger's Disease) is a rare, progressive, chronic
More news about: Calliditas Therapeutics
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
study3,dNearly 60% of adolescents treated with ICOTYDE achieved completely clear skin (57% PASI 100, 61% IGA 0) at Week 52.In adolescents enrolled in ICONIC-LEAD, 86% achieved PASI 90 response at one year, with 92% maintaining that response from Week
More news about: Johnson & Johnson
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
data were pooled. Proportions achieving NPF-defined remission (either continuous BSA=0% for ≥6 months or IGA=0 for ≥6 months) during the first year of BE VIVID/BE RADIANT, with no missing BSA/IGA measurements, are reported (observed case).1 These data were post hoc analyses and should be interpreted
More news about: UCB
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
75 %IGA 0,1‡68 %
More news about: Eli Lilly and Company
Mar 25, 2026, 06:45 ET IGT Shapes the Future of Gaming for Tribal Casino Operators at the 2026 Indian Gaming Tradeshow & Convention
("ETG") and CDS games at IGA. For more information on IGT's IGA portfolio visit www.igt.com/IGA or follow #IGTxIGA26 on
More news about: IGT
Mar 24, 2026, 11:00 ET Lumos Launches Identity Security Agents that Turn Intelligence into Enhanced Security Posture at Scale
governance tools that lack intelligence, Lumos connects the full loop from discovery to remediation to governance. Because Lumos is built on a full IGA backbone, agents can translate point-in-time security findings into durable policy, improving security posture with every action.AvailabilityLumos
More news about: Lumos
Mar 24, 2026, 07:30 ET Securden Unveils the World's First Truly Unified Identity Security Platform at RSA Conference 2026
Unifies PAM, EPM, IGA, CIEM, NHI, and AI Agent Security in a single package to protect human, machine, and AI identitiesSAN FRANCISCO, March 24, 2026 /PRNewswire/ --
More news about: Securden, Inc.
Mar 23, 2026, 08:30 ET The Glomerular Revolution: Understanding the New Wave of Breakthroughs in Rare Kidney Diseases, Upcoming Webinar Hosted by Xtalks
medical management of rare kidney diseases. This webinar will provide a comprehensive overview of the most prevalent rare kidney diseases, including IgA nephropathy (IgAN), primary membranous nephropathy (PMN), focal segmental glomerulonephritis (FSGS) and C3 glomerulopathy (C3G). It will also review
More news about: Xtalks
Mar 23, 2026, 06:59 ET Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
narcolepsy, and products in pivotal Phase 3 trials which are currently ongoing, such as selatogrel in acute myocardial infarction (AMI), Nefecon in IgA nephropathy, and cenerimod in systemic lupus erythematosus (SLE).About Viatris
More news about: Viatris Inc.
Mar 18, 2026, 08:03 ET Omada Appoints Jakob H. Kraglund as CEO to Accelerate Global Growth
generation of agentic and non-human identity governance. I look forward to working with the Omada team and our partners to deliver the next generation of IGA for AI to enterprises globally."With the updated leadership, Omada is well positioned to further accelerate growth as companies rethink identity
More news about: Omada
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
head-to-head trials versus an active comparator. In the head-to-head superiority studies, approximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved a Psoriasis Area and Severity Index (PASI) 90 response at Week 16.3,b,c Rates of
More news about: Johnson & Johnson
Mar 17, 2026, 13:13 ET Arango Launches Contextual Data Platform 4.0 for AI-Agent-Ready Enterprise Data
capabilities."Customer Perspective from Cybersecurity: Identity Security Company"Identity security can't wait for manual processes. Our AI Native IGA reasons across complex relationships between users, roles, applications, and entitlements in real time," said Israel Duanis, CEO, Linx Security.
More news about: Arango
Mar 17, 2026, 09:00 ET Orchid Security Recognized by Gartner® as a Representative Vendor of Guardian Agents
and large language models to unify fragmented identity operations. Global organizations rely on Orchid to modernize identity governance, accelerate IGA adoption, and secure the next generation of applications and AI agents.ContactChloe AmanteMontner Tech PR
More news about: Orchid Security
Mar 17, 2026, 08:00 ET 禮邦醫藥宣佈與 R1 Therapeutics 達成 AP306 股權及海外授權合作協議
禮邦醫藥是一家專注於腎臟領域的生物製藥公司，擁有涵蓋研發、生產和商業化的垂直整合平臺。公司擁有全面的創新腎臟管線組合，涵蓋七款在研藥物和一款已上市產品（Mircera®），覆蓋廣泛的腎臟適應症，包括 CKD 併發症（高磷血症、腎性貧血）、IgA 腎病、糖尿病腎病、FSGS 和 ADPKD。禮邦醫藥持有核心管線資產的全球權利，包括 AP301（一款同類最優的口服鐵基磷結合劑，目前已完成中國註冊性 3 期臨床並同步開展全球 3 期臨床）、AP306（一款同類首創的泛磷酸鹽轉運蛋白抑制劑）、AP303（一款同類首創的雙重 PPAR 激動劑，已獲 FDA 孤兒藥資格認定，適應症為 ADPKD）及 AP308（一款同類首創的 IgA 蛋白酶）。公司已在中國揚州建成生產基地，並已在中國組建了專屬的商業化團隊。關於
More news about: Alebund Pharmaceuticals
Mar 17, 2026, 08:00 ET Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
and one commercialized product (Mircera®) targeting a broad range of renal indications including CKD complications (hyperphosphatemia, renal anemia), IgA nephropathy, diabetic kidney disease, FSGS, and ADPKD. Alebund holds global rights for its core pipeline assets, including AP301 (a best-in-class oral
More news about: Alebund Pharmaceuticals
Mar 16, 2026, 10:45 ET One Identity is Recognized as a Progressive Company in the MarketsandMarkets' 360Quadrants for the Identity and Access Management (IAM) Market
Safeguard, Active Roles, and OneLogin, delivering capabilities such as identity governance and administration (IGA),
More news about: MarketsandMarkets
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
weeks before randomization and throughout the 16-week study but could be decreased or stopped once patients achieved IGA 2 or less. The co-primary endpoints in ADorable-1 were EASI-75 and IGA 0,1 at Week 16. Key secondary endpoints included an even greater clinical improvement in disease severity (EASI-90)
More news about: Eli Lilly and Company
Mar 12, 2026, 09:00 ET Century Health and Dallas Renal Group Partner to Unlock Real-World Insights on Rare Kidney Diseases
Rare kidney diseases such as IgA nephropathy and C3 glomerulopathy are difficult to track in electronic records because key diagnostic signals often live in reports and notes Century Health's AI will identify and structure signals across practices, creating
More news about: Century Health